Targeting specific proteins to improve treatment for advanced endometrial cancer
Project 1: Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy
This study is testing a new drug called SHetA2 to help women with advanced or recurring endometrial cancer by targeting specific proteins in cancer cells, with the goal of finding safer and more effective treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10912613 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for women suffering from advanced or recurrent endometrial cancer, a type of cancer that has seen rising incidence and mortality rates. The approach involves targeting heat shock proteins that are elevated in cancer cells, using a drug called SHetA2 that disrupts the survival mechanisms of these cancer cells while sparing healthy cells. The research includes preclinical studies and is currently in a Phase 1 clinical trial to assess the drug's safety and effectiveness in patients. By understanding the molecular profiles of endometrial cancer, the research aims to provide more effective and less toxic treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with advanced, recurrent, or persistent endometrial cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage endometrial cancer or those whose cancer is not recurrent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for women with advanced endometrial cancer.
How similar studies have performed: Other research has shown promise in targeting heat shock proteins in cancer therapy, indicating that this approach may be effective.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Benbrook, Doris Mangiaracina — Washington University
- Study coordinator: Benbrook, Doris Mangiaracina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.